14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
23 Jul 2025 Date | | - Cons. EPS | - EPS |
21 Jul 2025 Date | | - Cons. EPS | - EPS |
16 Jul 2025 Date | | - Cons. EPS | - EPS |
14 Jul 2025 Date | | - Cons. EPS | - EPS |
14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
23 Jul 2025 Date | | - Cons. EPS | - EPS |
21 Jul 2025 Date | | - Cons. EPS | - EPS |
16 Jul 2025 Date | | - Cons. EPS | - EPS |
14 Jul 2025 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Marc Lustig M.B.A., M.Sc. CEO | OTC PINK Exchange | CA71716K1012 ISIN |
CA Country | - Employees | - Last Dividend | 18 Jan 2019 Last Split | - IPO Date |
PharmaCielo Ltd. is a prominent entity in the medicinal cannabis industry, with a robust operation that spans cultivation, processing, production, and supply of medicinal-grade cannabis extracts, tetrahydrocannabinol (THC), and related products. The company is distinctive for its comprehensive approach to the cannabis sector, serving a diverse clientele that includes health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies primarily in Canada and Colombia. Headquartered in Toronto, Canada, PharmaCielo distinguishes itself with its international operations and a strategic partnership with Benuvia Operations, LLC. This partnership is focused on manufacturing cGMP (Current Good Manufacturing Practice) pharmaceutical-grade CBD isolate and other related products, signaling PharmaCielo's commitment to quality and regulatory compliance in the burgeoning field of medicinal cannabis.